Hamlet Pharma
Business Services · 11-50 Employees
View Company Info for Free
Overview
Phone Number
+46 40122500Website
www.hamletpharma.comRevenue
$8.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Hamlet Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in human milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects against bladder cancer in animal models. In an ongoing clinical trial with Alpha1H in patients with bladder cancer, potent tumor responses have been demonstrated compared to patients who received placebo. The results from the ongoing clinical study show no drug-related side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Bladder cancer is a common and costly form of cancer that is difficult to treat and has been decRead more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hamlet Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Hamlet Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Hamlet Pharma is spiking on competitors!
Product Launch: Get notified when Hamlet Pharma launches new products
Check if Hamlet Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Hamlet Pharma
Click to see if Hamlet Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Hamlet Pharma has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Hamlet Pharma recently announced quarterly report
Recommended Actions
Find VP level buyers at Hamlet Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
Hamlet Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hamlet Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hamlet Pharma.
Hamlet Pharma Tech Stack
A closer look at the technologies used by Hamlet Pharma
See more technologies
Most Recent Scoops
New Hire
Executive Move
New Hire
Executive Move
Mergers & Acquisitions (M&A)
Left Company
Executive Move
New Hire
Executive Move
Hamlet Pharma News & Media
FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer
Hamlet Pharma is proud to announce today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Alpha1H, a highly selective synthetic peptide for treatment of non-muscle invasive bladder (NMIBC). Working closely with their US based partner, Target Health LLC, a New Jersey-based, full-service CRO, the FDA’s ‘Study May Proceed’ letter begins a hopeful new chapter for the treatment of NMIBC patients globally. Studies with Alpha1H show aPetter Segelman Lindqvist appointed new CEO of Hamlet Pharma
Hamlet Pharma, soon to be Hamlet BioPharma, the innovative pharmaceutical company with several projects in Phase II trials in infection and cancer and an extensive project and patent portfolio, announces the appointment of Petter Segelman Lindqvist as new CEO, starting October 1[st] 2023. The recruitment of Petter Segelman Lindqvist marks a new phase in the development of Hamlet BioPharma’s groundbreaking technologies for cancer and infection therapy. Petter Segelman Lindqvist’s extensive experiHamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group
Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1. The new production, at a larger scale, will be essential for future expansions of the clinical trial programHamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET
Lund, June 9, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, invites to investor presentation at Aktiespararnas Capital Market Day on June 12 in Stockholm. The founder and Chairman Catharina Svanborg will present at 13.30 CET on June 12 at Birger Jarlsgatan 61 A. Sign up here to participate in Stockholm: https://www.aktiespararna.se/aktiviteter/smabolagsdagarna-i-stockholm-12-juni Fo
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hamlet Pharma
Sign Up For FreeTo access detailed company insights
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in human milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal mo... Read More
